GSK, Vivalis get green light to test new vax tech

The push to get better, faster vaccine technology in place took a step forward with the news that France's Vivalis and GlaxoSmithKline have won FDA approval to begin clinical trials of a new flu jab using duck stem cell line EB66 technology. Vivalis says the regulatory green light could pave the way to an approval for the first such new vaccine as early as 2015. Story

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.